News from neurosigma, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 10, 2015, 07:00 ET Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

 NeuroSigma, Inc. (NeuroSigma), today announced positive preliminary findings from a clinical study using non-invasive external Trigeminal...


Nov 16, 2015, 05:00 ET NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for...


May 04, 2015, 07:00 ET NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its...


Nov 17, 2014, 07:00 ET NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...


Nov 03, 2014, 07:00 ET NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...


Oct 15, 2014, 07:00 ET NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...


Aug 26, 2014, 18:45 ET NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

 NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has...


Aug 25, 2014, 07:00 ET U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...


Jul 09, 2014, 07:00 ET NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...


Jul 08, 2014, 07:00 ET Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...


Jun 03, 2014, 07:00 ET Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...


Apr 01, 2014, 07:00 ET NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

 NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System...


Feb 25, 2014, 07:00 ET David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...


Feb 11, 2014, 06:00 ET Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...


Jan 27, 2014, 06:00 ET Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...


Jul 29, 2013, 08:00 ET NeuroSigma Announces FDA Approval to Commence Phase III Trial

 NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption...


Jun 21, 2013, 06:00 ET NeuroSigma Announces Debut of Its Monarch eTNS System in Canada

 NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch™ eTNS™ System for the adjunctive...


May 02, 2013, 06:00 ET NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its...


Apr 18, 2013, 03:01 ET Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD

 NeuroSigma, Inc., a California-based medical device company, today announced that the results of the first-ever pediatric clinical trial of...


Mar 25, 2013, 03:01 ET External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus

NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch™...


Feb 11, 2013, 03:01 ET NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London

NeuroSigma, Inc., a California-based medical device company, today announced that Christopher DeGiorgio, M.D., Vice President of Neurology at...


Feb 04, 2013, 07:00 ET NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy

NeuroSigma, Inc., a California-based medical device company, today announced it received a Notice of Award, for a Fast Track Small Business...


Jan 30, 2013, 17:46 ET NeuroSigma Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®

 NeuroSigma, Inc., a California-based medical device company, today announced the publication of a positive Phase II clinical study for the use...


Sep 25, 2012, 04:00 ET NeuroSigma's Monarch eTNS System to be Unveiled in London

 NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch™ eTNS™ system for the...


Jul 02, 2012, 06:00 ET NeuroSigma Receives Global Quality Control Certification

 Today NeuroSigma, Inc., a Los Angeles-based medical device company, announced that it received ISO 13485: 2003 certification, indicating that...